Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Prospective Study of the Efficacy of Propranolol on Malignant Melanoma Progression. A Randomized Placebo-controlled,Single Blind Trial

NCT01988831 is registered in ClinicalTrials.gov with University Hospital, Geneva as lead sponsor.

NCT NCT01988831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01988831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Prospective Study of the Efficacy of Propranolol on Malignant Melanoma Progression. A Randomized Placebo-controlled,Single Blind Trial
Lead sponsor
University Hospital, Geneva
Phase
Phase 2
Overall status
Suspended
Start date
June 30, 2016
Completion date
March 31, 2022
Enrollment
450 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage ib skin melanoma, stages ii skin melanoma, stages iii skin melanoma